Cellular evaluation of oral chemotherapy carriers

被引:22
作者
Blanchette, J
Peppas, NA
机构
[1] Univ Texas, Dept Biomed Engn, Austin, TX 78712 USA
[2] Univ Texas, Dept Chem Engn, Austin, TX 78712 USA
[3] Univ Texas, Div Pharmaceut, Austin, TX 78712 USA
关键词
oral administration; hydrogel; bleomycin; caco-2; cells; cancer;
D O I
10.1002/jbm.a.30243
中图分类号
R318 [生物医学工程];
学科分类号
0831 [生物医学工程];
摘要
Hydrogel nanospheres composed of methacrylic acid and poly(ethylene glycol) were loaded with bleomycin and tested as a potential oral delivery system for chemotherapeutic agents. The gastrointestinal epithelium was modeled through the use of Caco-2 monolayers for studies of permeation enhancement by the carriers as well as bleomycin transport. Bleomycin efficacy following release from the carrier was evaluated with a DLD-1 tumor cell model. The nanospheres release bleomycin in response to a pH increase similar to that seen when passing from the stomach into the upper small intestine. These carriers can also increase the permeability of a model of the epithelial barrier, which would hopefully improve drug transport into the bloodstream. Efficacy studies using a tumor cell model showed retention of activity for bleomycin following loading and release from the nanospheres. The carriers described performed well during in vitro evaluation and can hopefully expand the spectrum of chemotherapeutic agents capable of being administered orally. (C) 2005 Wiley Periodicals, Inc.
引用
收藏
页码:381 / 388
页数:8
相关论文
共 23 条
[1]
Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? [J].
Behrens, I ;
Kissel, T .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 19 (05) :433-442
[2]
Blanchette J, 2002, MATER RES SOC SYMP P, V724, P215
[3]
Bleomycins: new methods will allow reinvestigation of old issues [J].
Chen, JY ;
Stubbe, JA .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (02) :175-181
[4]
Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts [J].
De Cesare, M ;
Zunino, F ;
Pace, S ;
Pisano, C ;
Pratesi, G .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (12) :1558-1564
[5]
Delie F, 1997, CRIT REV THER DRUG, V14, P221
[6]
Oral controlled release technology for peptides: Status and future prospects [J].
Fix, JA .
PHARMACEUTICAL RESEARCH, 1996, 13 (12) :1760-1764
[7]
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer [J].
Gore, M ;
Oza, A ;
Rustin, G ;
Malfetano, J ;
Calvert, H ;
Clarke-Pearson, D ;
Carmichael, J ;
Ross, G ;
Beckman, RA ;
Fields, SZ .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (01) :57-63
[8]
Clinical experience with topotecan in relapsed ovarian cancer [J].
Herzog, TJ .
GYNECOLOGIC ONCOLOGY, 2003, 90 (03) :S3-S7
[9]
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].
Hoff, PM ;
Ansari, R ;
Batist, G ;
Cox, J ;
Kocha, W ;
Kuperminc, M ;
Maroun, J ;
Walde, D ;
Weaver, C ;
Harrison, E ;
Burger, HU ;
Osterwalder, B ;
Wang, AO ;
Wong, R .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292
[10]
Oral vinorelbine for the treatment of metastatic non-small cell lung cancer in elderly patients: a phase II trial of efficacy and toxicity [J].
Kanard, A ;
Jatoi, A ;
Castillo, R ;
Geyer, S ;
Schulz, TK ;
Fitch, TR ;
Rowland, KM ;
Nair, S ;
Krook, JE ;
Kugler, JW .
LUNG CANCER, 2004, 43 (03) :345-353